title: Do we need guideline-driven specific lipid goals to achieve regression of coronary atherosclerosis and maximize therapy benefits?
authors.affiliation: Thessaloniki, Greece.
authors.forename: Vasilios Gabriel
authors.initials: VG
authors.lastname: Athyros
authors.affiliation: Thessaloniki, Greece.
authors.forename: Niki
authors.initials: N
authors.lastname: Katsiki
authors.affiliation: London, United Kingdom.
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
mesh_terms: D002097:C-Reactive Protein / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000097:blood*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D058226:Plaque, Atherosclerotic / Q000097:blood*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D002097:C-Reactive Protein